-
Notifications
You must be signed in to change notification settings - Fork 19
New issue
Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.
By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.
Already on GitHub? Sign in to your account
Impact of CYP & P-gp on bioavailability #364
Comments
Hi Robin, I am not aware of any work that explicitly looks into estimating the impact of first-pass CYP3A4 metabolism and P-gp transport. The closest to what you are looking for is a very recent publication on CYP3A4 and P-gp DDI in PK-Sim: Open-Systems-Pharmacology/OSP-based-publications-and-content#191 Within PK-Sim, there is no direct way to separately assess impact of the different routes (e.g. intestinal vs. hepatic) either with a sensitivity analysis or a population simulation, but you can do so after exporting the model to MoBi. You could, of course, also do this via the Matlab or R interface with your own scripted sensitivity analysis. Hope this helps as a start, |
Hi Robin |
Yes, @Aedginto is certainly right. You can do it in this very convenient way by simply changing the expression values. Thanks for adding this. I was somewhat in the automated relative assessment mode. |
Closing. Please reopen if you need more help |
Hello OSP !
I am currently working on a project with compounds that are both P-gp substrate molecules and are metabolized by CYP3A4. Some of these compounds show very low bioavailability in vivo. I am interested in using the software to determine the impact of P-gp and CYP3A4 (isolated AND combined) on bioavailability and particularly on first pass gut effect.
Has anyone tried to do this before? If so, could you share your conclusions and the information of how to explore it in PK-sim?
Many thanks in advance
Best regards,
Robin
The text was updated successfully, but these errors were encountered: